Congratulations Shiladitya Sengupta, Venkateswarlu Nelabhotla, and the @vyomebio team for achieving a new milestone with fresh round of funds. #KalaariFamily Iron Pillar @romuluscap tech.economictimes.indiatimes.com/news/startups/…

Vyome Therapeutics announces the closing of a $22 million fund raise. With our HQ now located in the US, we eagerly look forward to Vyome’s future as we continue advancing novel treatments in dermatology that address the problem of antimicrobial resistance bit.ly/2CNWovB

Greetings from #biotechshowcase and #JPM2019! With our recent closing of a $22M financing, Vyome Therapeutics is pleased to be here in SFO, and looks forward to continued development of VB 1953 in #antibioticresistant #acne. Learn more on our website vyometx.com

11/01/2019: ByFoodtech Seems Hottest for Investment & Vernacular Space is Catching Up too #4ThingsToKnow for #Entrepreneurs By: Bhavya Kaushal #Foodtech, #InnerChef, #VR, #Flipspaces, Vyome Therapeutics, Inc., Pratilipi

Vyome is now located in Princeton, NJ! Following this move and our recent financing, we continue to eagerly pursue the development of our pipeline of novel molecules to treat #antimicrobialresistant diseases.

Vyome welcomes Mohanjit Jolly to our board of directors and congratulates Dr. Chris Garabedian on his appointment to executive chairman. These talented team members will help drive drug development through clinical trials. #dermatology #drugdevelopment

After landing a $22M series D, Vyome Therapeutics, Inc. is working toward a phase IIb trial of its lead candidate, VB-1953 for treatment of moderate to severe acne. Check out tomorrow's edition of BioWorld for @TVPadma's interview with CEO Venkateswarlu Nelabhotla.

As the problem of #antibioticresistant #acne grows, so does the urgent need for viable treatment options. Vyome strives to continue developing VB 1953 to address this need as we look forward to the initiation of its phase 2b trial beginning in the first quarter of 2019.

In @LifeSciLeader1's latest #CompaniesToWatch column, Wayne Koberstein features a profile of Vyome Therapeutics and an interview of our CEO. Venkat discusses Vyome’s upcoming trial in #treatment-resistant #acne, affecting 10 million patients in the US bit.ly/VyomeTx_LSL

Vyome Therapeutics to Present Clinical Data on VB-1953 at the 2019 Society for Investigative Dermatology Annual Meeting bit.ly/2LvZV8f

We dosed the first patient in our Phase 2 trial of our lead clinical candidate, VB-1953, for the treatment of moderate to severe #inflammatory #acne vulgaris in April. The trial is progressing well, and we look forward to data readout in early 2020. bit.ly/2w0ivL7

We presented positive results from two key clinical trials testing our lead anti-acne candidate, VB-1953, at the annual #SIDChicago meeting. See press release for details: bit.ly/2VLTr9U

.Vyome Therapeutics, Inc. CEO Venkat Nelabhotla spoke with @medicialresearchnews about the recent positive results from our investigator-led study of VB-1953. He discusses the study’s background, promising findings, key takeaways, and more. Read the full interview here: bit.ly/2W9ipjQ

N. Venkat, CEO of Vyome Therapeutics, Inc., and Marie Daghlian with @big3bio discussed the company’s drug candidate VB-1953 being developed for the treatment of antibiotic resistant #acne. #BIO2019 Venkat Nelabhotla

#DYK that over 10 million patients in the US are #resistant to current topical #acne treatments? We are striving to address this unmet need with a deep pipeline of novel drugs for anti-resistant #acne and other opportunistic skin pathogens. bit.ly/2Qg5Z3t

While moderate to severe acne is most common among teenagers, it affects people of all ages. To learn more about the work Vyome Therapeutics, Inc. is doing to advance novel treatments in dermatology, visit our website: bit.ly/2VNRUAc

#podcast Venkat Nelabhotla @Vyometx on growing problem of antimicrobial resistance & tackling resistant dermatological conditions using understanding of skin #microbiome to treat #acne w/VB-1953 topical gel capable of killing resistant strains of P. acnes empoweredpatientradio.com/skin-microbiom…

Our CEO Venkat Nelabhotla spoke with EmpoweredPatient on the Empowered Patient #podcast about targeting the skin #microbiome to treat antibacterial-resistant #acne. VB1953 is a topical gel being developed by Vyome to kill resistant strains of C. acnes. bit.ly/2SvhWTW

The AARS society is an alliance of dermatology medical professionals dedicated to elevating the understanding and treatment of #acne and #rosacea. We commend the work they do and encourage followers to learn more about AARS here: bit.ly/2RzfivX

Vyome is proud to introduce Craig Tooman as our new COO and CFO! Craig brings decades of executive experience in our industry that will strengthen Vyome's leadership team as we advance our lead clinical candidate, VB-1953, through clinical development. bit.ly/2s57A4s